Cargando…
Gene therapy for cystic fibrosis: Challenges and prospects
Cystic fibrosis (CF) is a life-threatening autosomal-recessive disease caused by mutations in a single gene encoding cystic fibrosis transmembrane conductance regulator (CFTR). CF effects multiple organs, and lung disease is the primary cause of mortality. The median age at death from CF is in the e...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592762/ https://www.ncbi.nlm.nih.gov/pubmed/36304167 http://dx.doi.org/10.3389/fphar.2022.1015926 |
_version_ | 1784815001322651648 |
---|---|
author | Sui, Hongshu Xu, Xinghua Su, Yanping Gong, Zhaoqing Yao, Minhua Liu, Xiaocui Zhang, Ting Jiang, Ziyao Bai, Tianhao Wang, Junzuo Zhang, Jingjun Xu, Changlong Luo, Mingjiu |
author_facet | Sui, Hongshu Xu, Xinghua Su, Yanping Gong, Zhaoqing Yao, Minhua Liu, Xiaocui Zhang, Ting Jiang, Ziyao Bai, Tianhao Wang, Junzuo Zhang, Jingjun Xu, Changlong Luo, Mingjiu |
author_sort | Sui, Hongshu |
collection | PubMed |
description | Cystic fibrosis (CF) is a life-threatening autosomal-recessive disease caused by mutations in a single gene encoding cystic fibrosis transmembrane conductance regulator (CFTR). CF effects multiple organs, and lung disease is the primary cause of mortality. The median age at death from CF is in the early forties. CF was one of the first diseases to be considered for gene therapy, and efforts focused on treating CF lung disease began shortly after the CFTR gene was identified in 1989. However, despite the quickly established proof-of-concept for CFTR gene transfer in vitro and in clinical trials in 1990s, to date, 36 CF gene therapy clinical trials involving ∼600 patients with CF have yet to achieve their desired outcomes. The long journey to pursue gene therapy as a cure for CF encountered more difficulties than originally anticipated, but immense progress has been made in the past decade in the developments of next generation airway transduction viral vectors and CF animal models that reproduced human CF disease phenotypes. In this review, we look back at the history for the lessons learned from previous clinical trials and summarize the recent advances in the research for CF gene therapy, including the emerging CRISPR-based gene editing strategies. We also discuss the airway transduction vectors, large animal CF models, the complexity of CF pathogenesis and heterogeneity of CFTR expression in airway epithelium, which are the major challenges to the implementation of a successful CF gene therapy, and highlight the future opportunities and prospects. |
format | Online Article Text |
id | pubmed-9592762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95927622022-10-26 Gene therapy for cystic fibrosis: Challenges and prospects Sui, Hongshu Xu, Xinghua Su, Yanping Gong, Zhaoqing Yao, Minhua Liu, Xiaocui Zhang, Ting Jiang, Ziyao Bai, Tianhao Wang, Junzuo Zhang, Jingjun Xu, Changlong Luo, Mingjiu Front Pharmacol Pharmacology Cystic fibrosis (CF) is a life-threatening autosomal-recessive disease caused by mutations in a single gene encoding cystic fibrosis transmembrane conductance regulator (CFTR). CF effects multiple organs, and lung disease is the primary cause of mortality. The median age at death from CF is in the early forties. CF was one of the first diseases to be considered for gene therapy, and efforts focused on treating CF lung disease began shortly after the CFTR gene was identified in 1989. However, despite the quickly established proof-of-concept for CFTR gene transfer in vitro and in clinical trials in 1990s, to date, 36 CF gene therapy clinical trials involving ∼600 patients with CF have yet to achieve their desired outcomes. The long journey to pursue gene therapy as a cure for CF encountered more difficulties than originally anticipated, but immense progress has been made in the past decade in the developments of next generation airway transduction viral vectors and CF animal models that reproduced human CF disease phenotypes. In this review, we look back at the history for the lessons learned from previous clinical trials and summarize the recent advances in the research for CF gene therapy, including the emerging CRISPR-based gene editing strategies. We also discuss the airway transduction vectors, large animal CF models, the complexity of CF pathogenesis and heterogeneity of CFTR expression in airway epithelium, which are the major challenges to the implementation of a successful CF gene therapy, and highlight the future opportunities and prospects. Frontiers Media S.A. 2022-10-11 /pmc/articles/PMC9592762/ /pubmed/36304167 http://dx.doi.org/10.3389/fphar.2022.1015926 Text en Copyright © 2022 Sui, Xu, Su, Gong, Yao, Liu, Zhang, Jiang, Bai, Wang, Zhang, Xu and Luo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Sui, Hongshu Xu, Xinghua Su, Yanping Gong, Zhaoqing Yao, Minhua Liu, Xiaocui Zhang, Ting Jiang, Ziyao Bai, Tianhao Wang, Junzuo Zhang, Jingjun Xu, Changlong Luo, Mingjiu Gene therapy for cystic fibrosis: Challenges and prospects |
title | Gene therapy for cystic fibrosis: Challenges and prospects |
title_full | Gene therapy for cystic fibrosis: Challenges and prospects |
title_fullStr | Gene therapy for cystic fibrosis: Challenges and prospects |
title_full_unstemmed | Gene therapy for cystic fibrosis: Challenges and prospects |
title_short | Gene therapy for cystic fibrosis: Challenges and prospects |
title_sort | gene therapy for cystic fibrosis: challenges and prospects |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592762/ https://www.ncbi.nlm.nih.gov/pubmed/36304167 http://dx.doi.org/10.3389/fphar.2022.1015926 |
work_keys_str_mv | AT suihongshu genetherapyforcysticfibrosischallengesandprospects AT xuxinghua genetherapyforcysticfibrosischallengesandprospects AT suyanping genetherapyforcysticfibrosischallengesandprospects AT gongzhaoqing genetherapyforcysticfibrosischallengesandprospects AT yaominhua genetherapyforcysticfibrosischallengesandprospects AT liuxiaocui genetherapyforcysticfibrosischallengesandprospects AT zhangting genetherapyforcysticfibrosischallengesandprospects AT jiangziyao genetherapyforcysticfibrosischallengesandprospects AT baitianhao genetherapyforcysticfibrosischallengesandprospects AT wangjunzuo genetherapyforcysticfibrosischallengesandprospects AT zhangjingjun genetherapyforcysticfibrosischallengesandprospects AT xuchanglong genetherapyforcysticfibrosischallengesandprospects AT luomingjiu genetherapyforcysticfibrosischallengesandprospects |